Metformin--mode of action and clinical implications for diabetes and cancer (Q34658712)

3 August 2017

Metformin--mode of action and clinical implications for diabetes and cancer (English)

1 reference

3 August 2017

1 reference

2

Márta Korbonits

0 references

author name string

Ida Pernicova

series ordinal

1

1 reference

3 August 2017

Márta Korbonits

series ordinal

2

1 reference

3 August 2017

language of work or name

1 reference

7 January 2014

1 reference

Nature Reviews Endocrinology

3 August 2017

1 reference

3 August 2017

10

1 reference

3 August 2017

3

1 reference

3 August 2017

143-156

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2013.256

3 August 2017

0 references

cites work

Traditional plant medicines as treatments for diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin and its clinical use: new insights for an old drug in clinical practice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Meta-analysis: metformin treatment in persons at risk for diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

[Effect of metformin on the expression of tumor necrosis factor-α, Toll like receptors 2/4 and C reactive protein in obese type-2 diabetic patients].

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Diabetes and cancer: a consensus report.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Cardiovascular outcomes in trials of oral diabetes medications: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin increases insulin sensitivity and basal glucose clearance in Type 2 (non-insulin dependent) diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Effect of biguanides on intestinal absorption of glucose

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Role of organic cation/carnitine transporter 1 in uptake of phenformin and inhibitory effect on complex I respiration in mitochondria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Effect of metformin on fatty acid and glucose metabolism in freshly isolated hepatocytes and on specific gene expression in cultured hepatocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Contribution of gluconeogenesis to overall glucose output in diabetic and nondiabetic men.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Depolarization of the liver cell membrane by metformin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin inhibits glycogen synthesis and gluconeogenesis in cultured rat hepatocytes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Mechanism of Action of Metformin: Insulin Receptor and Postreceptor Effects in Vitro and in Vivo*

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Insulin Receptor Binding to Monocytes, Insulin Secretion, and Glucose Tolerance Following Metformin Treatment: Results of a Double-Blind Cross-Over Study in Type II Diabetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Mechanism of metformin action in non-insulin-dependent diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Enhanced secretion of glucagon-like peptide 1 by biguanide compounds

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Preservation of β-cell function: the key to diabetes prevention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Obligatory role of membrane events in the regulatory effect of metformin on the respiratory chain function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

An energetic tale of AMPK-independent effects of metformin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Role of AMP-activated protein kinase in mechanism of metformin action

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Cellular responses to the metal-binding properties of metformin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin activates AMP kinase through inhibition of AMP deaminase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Action of metformin on erythrocyte membrane fluidity in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

CREB regulates hepatic gluconeogenesis through the coactivator PGC-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

CREB and the CRTC co-activators: sensors for hormonal and metabolic signals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Inositol-1,4,5-trisphosphate receptor regulates hepatic gluconeogenesis in fasting and diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

AMPK-dependent repression of hepatic gluconeogenesis via disruption of CREB.CRTC2 complex by orphan nuclear receptor small heterodimer partner.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Fasting hyperglycemia is not associated with increased expression of PEPCK or G6Pc in patients with Type 2 Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Cytosolic phosphoenolpyruvate carboxykinase does not solely control the rate of hepatic gluconeogenesis in the intact mouse liver

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Balancing glycolytic flux: the role of 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatases in cancer metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin counters the insulin-induced suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Inhibition by AICA Riboside of Gluconeogenesis in Isolated Rat Hepatocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin and reduced risk of cancer in diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Association between metformin therapy and mortality after breast cancer: a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin and the risk of cancer: time-related biases in observational studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Investigating metformin for cancer prevention and treatment: the end of the beginning

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Multidrug and toxin extrusion proteins as transporters of antimicrobial drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Insulin glargine and cancer: another side to the story?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin suppresses intestinal polyp growth in ApcMin/+ mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Ragulator is a GEF for the rag GTPases that signal amino acid levels to mTORC1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

AMPK phosphorylation of raptor mediates a metabolic checkpoint

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

AMPK: opposing the metabolic changes in both tumour cells and inflammatory cells?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

LKB1 and AMPK and the cancer-metabolism link - ten years after

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Control of Glycolytic Flux by AMP-Activated Protein Kinase in Tumor Cells Adapted to Low pH

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Regulation of mTORC1 by the Rag GTPases is necessary for neonatal autophagy and survival.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin as an energy restriction mimetic agent for breast cancer prevention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin reduces endogenous reactive oxygen species and associated DNA damage

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin activates an ataxia telangiectasia mutated (ATM)/Chk2-regulated DNA damage-like response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin: a case of divide and conquer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

A comparison of uptake of metformin and phenformin mediated by hOCT1 in human hepatocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Relevance of the OCT1 transporter to the antineoplastic effect of biguanides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Adiponectin, obesity, and cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Transport of biguanides by human organic cation transporter OCT2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Lactic acidosis in biguanide-treated diabetics: a review of 330 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Lactic acidosis rates in type 2 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Effects of metformin on intestinal 5-hydroxytryptamine (5-HT) release and on 5-HT3 receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Phenformin as prophylaxis and therapy in breast cancer xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metabolic immunodepression and metabolic immunotherapy: an attempt of improvement in immunologic response in breast cancer patients by correction of metabolic disturbances

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Potential applications for biguanides in oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Involvement of carnitine/organic cation transporter OCTN1/SLC22A4 in gastrointestinal absorption of metformin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Targeting glucose metabolism for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

The role of dysregulated glucagon secretion in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Multiple mechanisms of GW-9508, a selective G protein-coupled receptor 40 agonist, in the regulation of glucose homeostasis and insulin sensitivity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

The effect of metformin on food intake and its potential role in hypothalamic regulation in obese diabetic rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Intracerebroventricular administration of metformin inhibits ghrelin-induced Hypothalamic AMP-kinase signalling and food intake.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Hunger states switch a flip-flop memory circuit via a synaptic AMPK-dependent positive feedback loop

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Acute effects of glucagon-like peptide-1 on hypothalamic neuropeptide and AMP activated kinase expression in fasted rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

UCP2 mediates ghrelin's action on NPY/AgRP neurons by lowering free radicals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin inhibits adenosine 5'-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Intracerebroventricular injection of metformin induces anorexia in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomized clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

FIBRINOLYTIC EFFECT OF METFORMIN IN CORONARY-ARTERY DISEASE

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Improved endothelial function with metformin in type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin, an antidiabetic agent, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin inhibits cytokine-induced nuclear factor kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Enhancing CD8 T-cell memory by modulating fatty acid metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Antidiabetic drug metformin alleviates endotoxin-induced fulminant liver injury in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Protective effect of metformin on periapical lesions in rats by decreasing the ratio of receptor activator of nuclear factor kappa B ligand/osteoprotegerin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Antidiabetic drug metformin suppresses endotoxin-induced uveitis in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin downregulates Th17 cells differentiation and attenuates murine autoimmune arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Metformin reduces airway inflammation and remodeling via activation of AMP-activated protein kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2013.256

Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain

31 March 2020

1 reference

12 December 2020

Metformin: a review of its pharmacological properties and therapeutic use

1 reference

12 December 2020

Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells

1 reference

12 December 2020

Action of metformin on glucose transport and glucose transporter GLUT1 and GLUT4 in heart muscle cells from healthy and diabetic rats

1 reference

12 December 2020

Metformin therapy and kidney disease: a review of guidelines and proposals for metformin withdrawal around the world

1 reference

12 December 2020

United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years

1 reference

12 December 2020

Biguanide-associated lactic acidosis. Case report and review of the literature

1 reference

12 December 2020

Use of oral antidiabetic drugs (metformin and pioglitazone) in diabetic patients with breast cancer: how does it effect serum Hif-1 alpha and 8Ohdg levels?

1 reference

12 December 2020

[Effects of antidiabetic drug metformin on human breast carcinoma cells with different estrogen receptor expressing in vitro].

1 reference

12 December 2020

Metformin does not adversely affect hormonal and symptomatic responses to recurrent hypoglycemia

1 reference

12 December 2020

Cation and structural requirements for P site-mediated inhibition of adenylate cyclase

1 reference

12 December 2020

The antidiabetic drug metformin elevates receptor tyrosine kinase activity and inositol 1,4,5-trisphosphate mass in Xenopus oocytes.

1 reference

12 December 2020

Inhibitory effects of metformin on insulin and glucagon action in rat hepatocytes involve post-receptor alterations

1 reference

12 December 2020

Effects of metformin on fibrinogen levels in obese patients with type 2 diabetes.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2013.256

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference